Combination of 13-cis retinoic acid and interferon-α in the treatment of recurrent or refractory peripheral T-cell lymphoma

Chin Lun Huang, Zhong Zhe Lin, Ih Jen Su, Tsu Yi Chao, Hwei Fang Tien, Ming Chih Chang, Ming Che Huang, Woei Yau Kao, Jih Luh Tang, Kun Heui Yeh, Chiu Hwa Wang, Chih Hung Hsu, Mei Yin Liu, Ann Lii Cheng

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

We previously reported the therapeutic efficacy of 13-cis retinoic acid (13-cRA) in some subtypes of peripheral T-cell lymphoma (PTCL). This study sought to clarify if the addition of interferon-α2a (IFN-α2a), an agent with synergistic cytotoxicity with 13-cRA in many types of malignant cells, may be more effective in the treatment of PTCL. Eligible patients has histologically proven PTCL, which was recurrent after or refractory to anthracycline-containing systemic chemotherapy. The treatment included oral administration of 13-cRA 1 mg/kg/day, divided into three doses, and intramuscular injection of IFN-α2a 4.5 MU/m2, three times per week. From March 1995 to July 2000, a total of 17 patients, 10 men and 7 women, with a median age of 47 years (range, 18-77 years), were recruited. The histologic diagnosis included 7 cases of unspecified PTCL, 6 cases of Ki-1 anaplastic large cell lymphoma (ALCL), 1 case of angioimmunoblastic T-cell lymphoma, and 3 cases of angiocentric nasal NK/T cell lymphoma. They received a median of 1.7 months of treatment (range, 0.4-13.3 months). One patient refused further treatment due to toxicity. The doses of 13-cRA and IFN-α2a had to be decreased in 7 and 7 patients, respectively. Grade III/IV hematologic and non-hematologic toxicity developed in 2 and 5 patients, respectively. There were 5 partial responses (Ki-1, 4; unspecified PTCL, 1), with a total response rate of 31.3% (95% Cl, 5.7-56.8%). The median duration of response for the responders was 2.5 months (range, 0.8-7.2 months). The median overall survival for the entire group of patients was 3.6 months. In conclusion, a combination of 13-cRA and IFN-α2a is a useful salvage treatment for selected patients with recurrent or refractory PTCL, particularly those with the Ki-1 subtype. However, the data does not support that addition of IFN-α2a is superior to 13-cRA alone.

Original languageEnglish
Pages (from-to)1415-1420
Number of pages6
JournalLeukemia and Lymphoma
Volume43
Issue number7
Publication statusPublished - 2002
Externally publishedYes

Fingerprint

Peripheral T-Cell Lymphoma
Isotretinoin
Interferons
Anaplastic Large-Cell Lymphoma
T-Cell Lymphoma
Therapeutics
Salvage Therapy
Anthracyclines
Intramuscular Injections
Nose
Natural Killer Cells
Oral Administration
Drug Therapy
Survival

Keywords

  • 13-cis retinoic acid
  • Interferon-α
  • Ki-1 lymphoma
  • T-cell lymphoma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Huang, C. L., Lin, Z. Z., Su, I. J., Chao, T. Y., Tien, H. F., Chang, M. C., ... Cheng, A. L. (2002). Combination of 13-cis retinoic acid and interferon-α in the treatment of recurrent or refractory peripheral T-cell lymphoma. Leukemia and Lymphoma, 43(7), 1415-1420.

Combination of 13-cis retinoic acid and interferon-α in the treatment of recurrent or refractory peripheral T-cell lymphoma. / Huang, Chin Lun; Lin, Zhong Zhe; Su, Ih Jen; Chao, Tsu Yi; Tien, Hwei Fang; Chang, Ming Chih; Huang, Ming Che; Kao, Woei Yau; Tang, Jih Luh; Yeh, Kun Heui; Wang, Chiu Hwa; Hsu, Chih Hung; Liu, Mei Yin; Cheng, Ann Lii.

In: Leukemia and Lymphoma, Vol. 43, No. 7, 2002, p. 1415-1420.

Research output: Contribution to journalArticle

Huang, CL, Lin, ZZ, Su, IJ, Chao, TY, Tien, HF, Chang, MC, Huang, MC, Kao, WY, Tang, JL, Yeh, KH, Wang, CH, Hsu, CH, Liu, MY & Cheng, AL 2002, 'Combination of 13-cis retinoic acid and interferon-α in the treatment of recurrent or refractory peripheral T-cell lymphoma', Leukemia and Lymphoma, vol. 43, no. 7, pp. 1415-1420.
Huang, Chin Lun ; Lin, Zhong Zhe ; Su, Ih Jen ; Chao, Tsu Yi ; Tien, Hwei Fang ; Chang, Ming Chih ; Huang, Ming Che ; Kao, Woei Yau ; Tang, Jih Luh ; Yeh, Kun Heui ; Wang, Chiu Hwa ; Hsu, Chih Hung ; Liu, Mei Yin ; Cheng, Ann Lii. / Combination of 13-cis retinoic acid and interferon-α in the treatment of recurrent or refractory peripheral T-cell lymphoma. In: Leukemia and Lymphoma. 2002 ; Vol. 43, No. 7. pp. 1415-1420.
@article{654a8f86a9e04553b9e8d673c4840139,
title = "Combination of 13-cis retinoic acid and interferon-α in the treatment of recurrent or refractory peripheral T-cell lymphoma",
abstract = "We previously reported the therapeutic efficacy of 13-cis retinoic acid (13-cRA) in some subtypes of peripheral T-cell lymphoma (PTCL). This study sought to clarify if the addition of interferon-α2a (IFN-α2a), an agent with synergistic cytotoxicity with 13-cRA in many types of malignant cells, may be more effective in the treatment of PTCL. Eligible patients has histologically proven PTCL, which was recurrent after or refractory to anthracycline-containing systemic chemotherapy. The treatment included oral administration of 13-cRA 1 mg/kg/day, divided into three doses, and intramuscular injection of IFN-α2a 4.5 MU/m2, three times per week. From March 1995 to July 2000, a total of 17 patients, 10 men and 7 women, with a median age of 47 years (range, 18-77 years), were recruited. The histologic diagnosis included 7 cases of unspecified PTCL, 6 cases of Ki-1 anaplastic large cell lymphoma (ALCL), 1 case of angioimmunoblastic T-cell lymphoma, and 3 cases of angiocentric nasal NK/T cell lymphoma. They received a median of 1.7 months of treatment (range, 0.4-13.3 months). One patient refused further treatment due to toxicity. The doses of 13-cRA and IFN-α2a had to be decreased in 7 and 7 patients, respectively. Grade III/IV hematologic and non-hematologic toxicity developed in 2 and 5 patients, respectively. There were 5 partial responses (Ki-1, 4; unspecified PTCL, 1), with a total response rate of 31.3{\%} (95{\%} Cl, 5.7-56.8{\%}). The median duration of response for the responders was 2.5 months (range, 0.8-7.2 months). The median overall survival for the entire group of patients was 3.6 months. In conclusion, a combination of 13-cRA and IFN-α2a is a useful salvage treatment for selected patients with recurrent or refractory PTCL, particularly those with the Ki-1 subtype. However, the data does not support that addition of IFN-α2a is superior to 13-cRA alone.",
keywords = "13-cis retinoic acid, Interferon-α, Ki-1 lymphoma, T-cell lymphoma",
author = "Huang, {Chin Lun} and Lin, {Zhong Zhe} and Su, {Ih Jen} and Chao, {Tsu Yi} and Tien, {Hwei Fang} and Chang, {Ming Chih} and Huang, {Ming Che} and Kao, {Woei Yau} and Tang, {Jih Luh} and Yeh, {Kun Heui} and Wang, {Chiu Hwa} and Hsu, {Chih Hung} and Liu, {Mei Yin} and Cheng, {Ann Lii}",
year = "2002",
language = "English",
volume = "43",
pages = "1415--1420",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - Combination of 13-cis retinoic acid and interferon-α in the treatment of recurrent or refractory peripheral T-cell lymphoma

AU - Huang, Chin Lun

AU - Lin, Zhong Zhe

AU - Su, Ih Jen

AU - Chao, Tsu Yi

AU - Tien, Hwei Fang

AU - Chang, Ming Chih

AU - Huang, Ming Che

AU - Kao, Woei Yau

AU - Tang, Jih Luh

AU - Yeh, Kun Heui

AU - Wang, Chiu Hwa

AU - Hsu, Chih Hung

AU - Liu, Mei Yin

AU - Cheng, Ann Lii

PY - 2002

Y1 - 2002

N2 - We previously reported the therapeutic efficacy of 13-cis retinoic acid (13-cRA) in some subtypes of peripheral T-cell lymphoma (PTCL). This study sought to clarify if the addition of interferon-α2a (IFN-α2a), an agent with synergistic cytotoxicity with 13-cRA in many types of malignant cells, may be more effective in the treatment of PTCL. Eligible patients has histologically proven PTCL, which was recurrent after or refractory to anthracycline-containing systemic chemotherapy. The treatment included oral administration of 13-cRA 1 mg/kg/day, divided into three doses, and intramuscular injection of IFN-α2a 4.5 MU/m2, three times per week. From March 1995 to July 2000, a total of 17 patients, 10 men and 7 women, with a median age of 47 years (range, 18-77 years), were recruited. The histologic diagnosis included 7 cases of unspecified PTCL, 6 cases of Ki-1 anaplastic large cell lymphoma (ALCL), 1 case of angioimmunoblastic T-cell lymphoma, and 3 cases of angiocentric nasal NK/T cell lymphoma. They received a median of 1.7 months of treatment (range, 0.4-13.3 months). One patient refused further treatment due to toxicity. The doses of 13-cRA and IFN-α2a had to be decreased in 7 and 7 patients, respectively. Grade III/IV hematologic and non-hematologic toxicity developed in 2 and 5 patients, respectively. There were 5 partial responses (Ki-1, 4; unspecified PTCL, 1), with a total response rate of 31.3% (95% Cl, 5.7-56.8%). The median duration of response for the responders was 2.5 months (range, 0.8-7.2 months). The median overall survival for the entire group of patients was 3.6 months. In conclusion, a combination of 13-cRA and IFN-α2a is a useful salvage treatment for selected patients with recurrent or refractory PTCL, particularly those with the Ki-1 subtype. However, the data does not support that addition of IFN-α2a is superior to 13-cRA alone.

AB - We previously reported the therapeutic efficacy of 13-cis retinoic acid (13-cRA) in some subtypes of peripheral T-cell lymphoma (PTCL). This study sought to clarify if the addition of interferon-α2a (IFN-α2a), an agent with synergistic cytotoxicity with 13-cRA in many types of malignant cells, may be more effective in the treatment of PTCL. Eligible patients has histologically proven PTCL, which was recurrent after or refractory to anthracycline-containing systemic chemotherapy. The treatment included oral administration of 13-cRA 1 mg/kg/day, divided into three doses, and intramuscular injection of IFN-α2a 4.5 MU/m2, three times per week. From March 1995 to July 2000, a total of 17 patients, 10 men and 7 women, with a median age of 47 years (range, 18-77 years), were recruited. The histologic diagnosis included 7 cases of unspecified PTCL, 6 cases of Ki-1 anaplastic large cell lymphoma (ALCL), 1 case of angioimmunoblastic T-cell lymphoma, and 3 cases of angiocentric nasal NK/T cell lymphoma. They received a median of 1.7 months of treatment (range, 0.4-13.3 months). One patient refused further treatment due to toxicity. The doses of 13-cRA and IFN-α2a had to be decreased in 7 and 7 patients, respectively. Grade III/IV hematologic and non-hematologic toxicity developed in 2 and 5 patients, respectively. There were 5 partial responses (Ki-1, 4; unspecified PTCL, 1), with a total response rate of 31.3% (95% Cl, 5.7-56.8%). The median duration of response for the responders was 2.5 months (range, 0.8-7.2 months). The median overall survival for the entire group of patients was 3.6 months. In conclusion, a combination of 13-cRA and IFN-α2a is a useful salvage treatment for selected patients with recurrent or refractory PTCL, particularly those with the Ki-1 subtype. However, the data does not support that addition of IFN-α2a is superior to 13-cRA alone.

KW - 13-cis retinoic acid

KW - Interferon-α

KW - Ki-1 lymphoma

KW - T-cell lymphoma

UR - http://www.scopus.com/inward/record.url?scp=0036299626&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036299626&partnerID=8YFLogxK

M3 - Article

C2 - 12389622

AN - SCOPUS:0036299626

VL - 43

SP - 1415

EP - 1420

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 7

ER -